Arrivo BioVentures Emerges from Stealth Mode with a Robust Pipeline and Promising Data
Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder
Arrivo BioVentures Announces SP-624 Demonstrated Robust Efficacy in Females With Major Depressive Disorder in Phase 2 Study
Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor
Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis asset
How this Triangle drugmaker secured $45M amid brutal funding environment
Triangle biotech startup emerges with a bang – $49M and 4 drug candidates
Morrisville biotech emerges from stealth mode with 4 drugs in pipeline
New Arrivo: Triangle Pharma Wizards Put $49M to Work
What You Need to Know About Arrivo Bioventures
The Next Generation: Top 20 Life Science Startups to Watch in 2017
Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million
Serial BioPharma Entrepreneurial Team launches drug development firm Arrivo BioVentures
Fresh off raising $49M for Arrivo, biotech teammates ‘energized’
Arrivo BioVentures LLC says it raised $49 mln in equity financing
Jazz Pharma has led a $49 million round to launch Arrivo BioVentures
Arrivo debuts with $49M
How these Morrisville execs landing $49M from investors without a specific product to pitch
Solas BioVentures to Seek Up to $100M for Second Early-Stage Fund
Veteran biotech entrepeneurs launch new venture with $49M in funding
Targets licensing and developing four to six new drug candidates
Term Sheet – Venture Capital Deals
Drug Developer Arrivo BioVentures Launches with $49M
Morrisville Drugmaker Sees Promise in Depression Treatment, Advances to Pivotal Study